← Eichor
Study identifier: NCT06053476 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Optimal Postoperative Chest Tube and Pain Management in Patients Surgically Treated for Primary Spontaneous Pneumothorax (Pneumotrial)

Condition: Pneumothorax, Primary Spontaneous · VATS · Pain, Postoperative  ·  Sponsor: Maxima Medical Center

PhaseNA
Planned participants366
Who can joinAll sexes, 16 Years to no upper limit
Healthy volunteersNo

About this study

Guidelines lack high quality evidence on optimal postoperative chest tube and pain management after surgery for primary spontaneous pneumothorax (PSP). This results in great variability in postoperative care and length of hospital stay (LOS). Chest tube and pain management are prominent factors regarding enhanced recovery after thoracic surgery, and in standardised care they are crucial to improve quality of recovery and decrease LOS. Historically, postoperative chest tubes are left in place for at least a fixed number of 3-5 days, irrespective of absence of air leakage. This period was deemed necessary for adequate pleurodesis and prevention of recurrence. However, it is suggested that removal on the same day of surgery is safe and associated with a reduced LOS. Regarding postoperative pain management, thoracic epidural analgesia (TEA) is the gold standard for postoperative pain management following video-assisted thoracic surgery (VATS). Although the analgesic effect of TEA is clear, it is associated with hypotension and urinary retention. Therefore, unilateral regional techniques, such as paravertebral blockade (PVB), are developed. The investigators hypothesize that early chest tube removal accompanied by a single-shot paravertebral blockade (PVB) for analgesia is safe regarding pneumothorax recurrence and non-inferior regarding pain, but superior regarding LOS when compared to standard conservative treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Quirine C.A. van Steenwijk, MD  ·  +31-40888-7243  ·  quirine.van.steenwijk@mmc.nl

Frank J.C. van den Broek, MD, PhD  ·  +31-40888-8550  ·  frankvanden.broek@mmc.nl

Always discuss trial participation with your own doctor first.

Locations (1)

Maxima MCVeldhoven, NetherlandsRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06053476